FILE - In this Sept. 24, 2014 file photo, Lloyd Blankfein, Chairman and CEO of Goldman Sachs, speaks in a panel discussion at the Clinton Global Initiative in New York. Blankfein said that he has a form of lymphoma that is "highly curable." In a post on the firm's website Tuesday, Sept. 22, 2015, he underwent a series of tests after not feeling well for several weeks. (AP Photo/Mark Lennihan)
Republished September 22, 2015 - 2:25 PM
Original Publication Date September 22, 2015 - 5:30 AM
NEW YORK, N.Y. - Goldman Sachs CEO and Chairman Lloyd Blankfein has a form of lymphoma, but says that it is "highly curable."
Blankfein wrote on the firm's website Tuesday that he underwent a series of tests after not feeling well for several weeks. The executive said he'll receive chemotherapy in New York over the next several months as part of his cancer treatment plan.
He will be reducing his travel, but expects to be able to "work substantially as normal."
"My doctors' and my own expectation is that I will be cured," Blankfein said.
Last year JPMorgan Chase & Co. CEO Jamie Dimon disclosed he had throat cancer, for which he was successfully treated.
Born in the Bronx and raised in public housing, Blankfein has been a near-lifelong employee of Goldman, rising through the ranks in the firm's commodities trading business.
Blankfein replaced CEO Hank Paulson, who left the firm to become Treasury Secretary under President George W. Bush.
After less than a year on the job, Blankfein was faced with the worst U.S. financial crisis since the Great Depression and it defined his tenure at the firm.
While Goldman Sachs was forced to take billions in bailout money in a program set up by Paulson, it was largely considered one of the healthiest firms and did not suffer the same fate as rivals Bear Stearns and Lehman Brothers, which failed.
Goldman walked away a leaner but stronger and the collapse of its rivals helped Goldman secure its place as a leading consultant for large corporations. It recently became a member of the 30-component Dow Jones industrial average and is now looking to expand into new types of businesses and lending.
Shares of the New York company fell $3.63, or 2 per cent, to $179.72. Its shares are down 7 per cent this year.
News from © The Associated Press, 2015